drugset / Trial / NCT05718037

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

NCT05718037

RandomizedSequentialQuadruple-blindPrevention

Summary

This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.

Timeline

Start
2023-08-01
Primary completion
2024-01-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 0.5 ml Intramuscular

Indications